Natural OTCs prepare for lift off
This article is powered by OTC Bulletin & The Rose Sheet
Increasing demand for more natural products is opening up an enticing opportunity for consumer healthcare players.Tom Gallen explores the tools firms can use to make their brands stand out in this growing market.
You may also be interested in...
After accelerated approval in the US in April based on Phase II response rates, the company will seek full approval later this year based on a tripling of progression-free survival in a Phase III trial.
Positive data from a second Phase III trial will support regulatory filings for linzagolix in the US and Europe, but the GnRH agonist is behind two rival drugs: AbbVie's elagolix and Myovant's relugolix.
The US FDA has authorized marketing of a combination diagnostic that can detect either COVID-19 or influenza. The agency hopes to encourage development of additional similar tests before the fall flu season.